When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRTX - Amgen slips 4% premarket on early-stage MAG 510 data
Mirati Therapeutics Inc.
Amgen (NASDAQ:AMGN) is down 4% premarket on light volume after announcing updated data from a Phase 1 clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. The results were presented at the World Conference on Lung Cancer in Barcelona.
More news on: Amgen Inc., Mirati Therapeutics, Inc., Healthcare stocks news, Stocks on the move,